The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Clinical Trials Ongoing for Brodalumab

Clinical Trials Ongoing for Brodalumab

June 5, 2015 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Brodalumab, an interleukin (IL) 17 inhibitor, is currently in early clinical trials (Phase 1b and Phase 2) for a number of different autoimmune diseases.1 Amgen recently terminated its co-development and commercialization agreement with AstraZeneca for the brodalumab investigational program in trials for moderate to severe plaque psoriasis, psoriatic arthritis and axial spondyloarthritis. Amgen’s decision to sever ties with AstraZeneca for this compound was due to the potential for restrictive labeling (if approved) because of suicidal ideation and suicidal behavior already identified in brodalumab trials. AstraZeneca continues to investigate this agent.2

You Might Also Like
  • Brodalumab Approved for Plaque Psoriasis
  • Etanercept Biosimilar Approved in EU, Plus FDA Reviews Brodalumab for Plaque Psoriasis
  • FDA Approves Valeant’s Drug to Treat Plaque Psoriasis
Also By This Author
  • FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications

As of April 24, 2015, AstraZeneca’s plan was to have Amgen submit the New Drug Application in 2015 or 2016. There is a good chance this application will be delayed.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Three clinical trials have been completed investigating brodalumab for managing moderate to severe plaque psoriasis (n=4,342). The moderate to severe plaque psoriasis trials were either placebo controlled or used an active treatment arm (ustekinumab 45 mg or 90 mg). Endpoints at Week 12 included PASI and static physician’s global assessment (sPGA). In the placebo-controlled trial, brodalumab treatment led to significant improvements in clinical and patient reported outcomes.3 Open-label extensions for these studies are ongoing.

Three clinical trials for psoriatic arthritis (n=1,281) are ongoing. These trials compare two strengths of subcutaneous brodalumab (140 mg or 210 mg) to placebo. The primary endpoint of these trials is the ACR20 response at Week 16. A secondary endpoint in one of the three studies is a radiographic joint assessment and PASI 75, HAQ-PI and PSI. Estimated completion of all three of the psoriatic arthritis trials is expected in the first quarter of 2016.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Amgen. News Release: Amgen to terminate participation in co-development and commercialization of brodalumab. 2015 May 22.
  2. AstraZeneca. AstraZeneca Clinical Trials Appendix Anti-IL-17RA (brodalumab) Psoriasis & psoriatic arthritis development programmes. 2015 April 24.
  3. Papp K, Reich K, Leonardi C, et al. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: Results of AMAGINE-1, a Phase 3, randomized, double-blind, placebo-controlled study through week 12. 2015. J Amer Acad Dermatol. May;72(5):AB233–275.

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Amgen, AstraZeneca, axial spondyloarthritis (SpA), Biologics & Biosimilars, brodalumab, plaque psoriasis, Psoriatic Arthritis

You Might Also Like:
  • Brodalumab Approved for Plaque Psoriasis
  • Etanercept Biosimilar Approved in EU, Plus FDA Reviews Brodalumab for Plaque Psoriasis
  • FDA Approves Valeant’s Drug to Treat Plaque Psoriasis
  • Adverse Event Risk Data Drive Evaluation of Psoriasis Treatments

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)